Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEland Oil & Gas Regulatory News (ELA)

  • There is currently no data for ELA

Operational Update

16 Feb 2016 07:00

RNS Number : 1372P
Eland Oil & Gas PLC
16 February 2016
 

 

 

 

16 February 2016

 

Eland Oil & Gas PLC

 ("Eland" or the "Company" and, together with its subsidiaries, the "Group")

 

Operational update

 

Eland Oil & Gas PLC (AIM: ELA), an oil & gas production and development company operating in West Africa with an initial focus on Nigeria, is pleased to announce the following operational update:

 

George Maxwell, CEO of Eland, commented:

 

"The strong production performance from the Opuama field in OML40 continued throughout 2015, with production and uptime at record levels. Following a highly successful workover of Opuama-1 in Q4, production from the field increased by more than 50% to 4,500 bopd, and has remained at these higher levels since.

 

Following the successful work-over of Opuama-1, we now turn our attention to two further low capex, high production workovers on OML 40. We are excited by the prospect of completing the further workover opportunity on Opuama-3 within the next two months. This involves intervention on both production strings which we expect will increase gross production by a further 50 to 100 per cent. We also see the potential for re-entry, completion and production of Gbetiokun-1 well later this year. The successful completion of these two workover projects are expected to increase production on OML 40 without using a drilling rig and whilst the Opuama-5 production was disappointing, the anticipated incremental production gains from that well have been largely offset by the better than expected performance of Opuama-1.

 

At the year end of 2015 we had available cash of over $8m, having drawn only $15m of a $35m committed facility from Standard Chartered Bank. Our short-term focus on highly accretive workovers will insure that our capital expenditure requirements for 2016 remain modest.

 

Following the success of the Opuama-1 workover, we have placed renewed focus on low cost workover potential in the licence. It is most welcome that we have seen a material and sustainable increase in production from this initiative. With further workovers planned, we have a number of options to continue these production increases prior to commencement of the development drilling campaign. Whilst we await formal ratification of operatorship of OML40, our ability to substantially boost production via workover operations is extremely encouraging".

 

 

 

2015 HIGHLIGHTS

 

Operational

 

· Opuama exited the period with production at circa. 4,500 bopd (2,025 bopd net to Elcrest Exploration and Production Nigeria Ltd, Eland's joint venture company). Average uptime on the field remained high throughout the year and averaged 84%, with Q4 running at 82% uptime.

· Elcrest (Eland's joint venture company) recorded total liftings (unaudited) of 341,000 bbls of crude in 2015, a 195% increase on 2014. Elcrest has completed the loading and sale of 38,000 bbls so far in 2016.

· Elcrest undertook a highly successful workover on Opuama-1, which completed in November. A successful intervention in the field resulted in a material 50% increase in average gross production output to 4,500 bopd (2,025 bopd net to Elcrest)

· The Opuama-5 workover did not deliver the expected 400-600 bopd of incremental short term production from the E2000 reservoir due to higher than expected water cut and the well was shut in on the 20th of January 2016. However, the workover has provided valuable information on the E2000 reservoir, which will be a drilling target in future wells, while Opuama-5 will be utilised as a water disposal well which will result in significantly reduced tariffs and operating expenditure. In addition, the operational lessons learned resulted in increased efficiency during the recent Opuama-1 workover and have been incorporated in our planning of the forthcoming Opuama-3 workover.

 

Financial

 

· In 2015 the Company embarked upon a cost reduction programme in response to the falling oil price. We anticipate hitting our targeted reduction of 30% in operating costs by the end of Q1 2016.

· Cash and cash equivalents held as at 31 December 2015 of US$8.4 million (31 December 2014 US$15.0 million).

· A Reserve Based Lending (RBL) facility of up to $75 million was signed with Standard Chartered Bank to fund development of OML 40. Of this amount, $35 million has been committed. As at 31 December 2015, $15m had been drawn from the RBL. Due to their very attractive high production relative to capex spend, the workovers are excellent candidates to be worked into our Reserve Based Lending Facility.

 

Outlook

 

· The Opuama-3 workover is funded and scheduled for Q1-2016 and is expected to lead to a material increase in production from the Opuama field, which we believe could be in the order of 2,000-4,000 bopd (on a gross basis). Following detailed technical work, including interference testing in January 2016, it is planned to initiate production from the undeveloped D1000 Upper and D2000 reservoirs. Both are high quality reservoirs containing light oil and are at original (D1000 Upper) or near-original (D2000) conditions. The new zones will be perforated using a state of the art directional perforating system and are expected to flow at up to 2,000 bopd each.

· We are also currently evaluating the re-entry, completion and production of Gbetiokun-1 well, whilst continuing our evaluation and execution of additional work-over opportunities on OML 40.

· To the east, in OML 17, we are considering options of achieving early production at low cost from the Ubima Field discovery by re-entering, completing and producing well Ubima-1.

 

  

 

For further information:

 

Eland Oil & Gas PLC (+44 (0)1224 737300)

www.elandoilandgas.com

George Maxwell, CEO

Louis Castro, CFO

Finlay Thomson, IR

 

Canaccord Genuity Limited (+44 (0)20 7 523 8000)

Henry Fitzgerald O'Connor

Wei Loon Yap

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCDMGMZNKLGVZM
Date   Source Headline
17th Jul 20095:57 pmBUSStudies Presented at International Conference on Alzheimer's Disease Reveal Substantial Economic Costs and Caregiver Burden Associated with Alzheimer's Disease
16th Jul 20092:18 pmRNSResults of Annual General Meeting
13th Jul 200911:30 amBUSElan and Transition Therapeutics Announce Phase 1 Data Showing ELND005 Achieves Desired Concentrations in Brain Tissue and Cerebrospinal Fluid
10th Jul 20094:59 pmRNSCancellation of UK Listing
8th Jul 20097:00 amBUSElan Announces Webcast of Second Quarter 2009 Financial Results
3rd Jul 200910:57 amRNSBlock Listing Six Monthly Return
2nd Jul 200912:57 pmRNSHolding in Company
2nd Jul 200912:41 pmPRNJohnson & Johnson, Elan Announce Definitive Agreement
1st Jun 20097:00 amBUSSubset Data from Two Randomized Phase 3 Trials Show TYSABRI® Significantly Improves Health-Related Quality of Life for Crohn's Disease Patients with Prior Exposure or Inadequate Response to Anti-TNF? Therapy
29th May 20094:36 pmRNSPrice Monitoring Extension
29th May 20092:00 pmBUSRenee P. Tannenbaum, Pharm.D. Joins Elan as Executive Vice President and Chief Commercial Officer
29th May 200911:54 amBUSTotal Voting Rights
30th Apr 200912:16 pmBUSTotal Voting Rights
27th Apr 20093:35 pmRNSAnnual Report
14th Apr 20095:09 pmRNSHolding(s) in Company
27th Feb 20092:44 pmBUSTotal Voting Rights
25th Feb 200912:23 pmBUSDirector/PDMR Shareholding
12th Feb 20096:00 pmBUSDirector/PDMR Shareholding
12th Feb 20096:00 pmBUSDirector/PDMR Shareholding
9th Feb 20097:00 amBUSMS Patients Treated with TYSABRI® Remain Free of Disease Activity for Two Years, According to Data Published in the Lancet Neurology
4th Feb 20092:32 pmRNSHolding(s) in Company
3rd Feb 20093:57 pmRNSHolding(s) in Company
30th Jan 20094:33 pmRNSHolding(s) in Company
28th Jan 20094:24 pmRNSHolding(s) in Company
13th Jan 20097:00 amBUSElan Clarifies Duration of Bapineuzumab Phase 3 Trials
12th Jan 20095:21 pmRNSHolding(s) in Company
12th Jan 20097:00 amBUSTysabri Update
2nd Jan 200912:21 pmRNSTotal Voting Rights
18th Dec 20084:24 pmRNSBlock Listing Six Monthly Return
16th Dec 200811:00 amBUSDirector Declaration
16th Dec 20087:00 amBUSElan to Present at the 27th Annual JP Morgan Healthcare Conference
15th Dec 20083:02 pmBUSTysabri Update
12th Dec 20087:00 amBUSElan Announces Resource Realignment
28th Nov 200810:47 amBUSTotal Voting Rights
25th Nov 20087:00 amBUSMary Stutts to Join Elan as Senior Vice President and Head of Corporate Relations
20th Nov 20087:00 amBUSCarlos V. Paya, MD, PhD, to Join Elan as Company President
3rd Nov 20085:12 pmRNSDirector/PDMR Shareholding
31st Oct 20084:11 pmRNSHolding in Company
31st Oct 200812:01 pmRNSTotal Voting Rights
30th Oct 20084:13 pmRNSTysabri Update
3rd Oct 20085:56 pmRNSHolding in Company
30th Sep 20084:11 pmRNSTotal Voting Rights
22nd Sep 200811:26 amRNSHolding In Company
22nd Sep 20087:00 amRNSTysabri Demonstrates Sustained Improvement
11th Sep 20087:39 amRNSDirector /PDMR Shareholding
1st Sep 20085:02 pmRNSHolding(s) in Company
29th Aug 200810:54 amRNSTotal Voting Rights
28th Aug 20087:00 amRNSInterim Results
14th Aug 20084:12 pmRNSHolding in Company
13th Aug 20085:22 pmRNSHolding in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.